Magnostics is developing two products that enable rapid diagnosis of Acute Mesenteric Ischemia, which is a hard-to-detect and deadly condition. Every 30 minutes of delay in diagnosis increases the mortality rate from AMI by about 5%. Our team has designed and validated a biomarker for blood tests that allows early diagnosis: Villin-1. We anticipate a mortality rate reduction from our test of up to 75% and we think we can achieve $113M ARR by 2032